Clinical and endocrine features of orthostatic intolerance detected in patients with long COVID.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
24 Jul 2024
Historique:
received: 29 02 2024
accepted: 16 07 2024
medline: 24 7 2024
pubmed: 24 7 2024
entrez: 23 7 2024
Statut: epublish

Résumé

Orthostatic intolerance (OI) is a key symptom of long COVID; however, the pathophysiology remains unknown. Among 688 long COVID patients who visited our clinic during the period from February 2021 to April 2023, 86 patients who were suspected of having OI and who underwent an active standing test (ST) were investigated to elucidate the clinical characteristics of OI in patients with long COVID. Of the 86 patients, 33 patients (38%) were ST-positive. Nausea and tachycardia in daily life were frequent complaints in the ST-positive group. The increase in heart rate (HR) during the ST was significantly greater during a 10-min period after standing in the ST-positive group (+ 30 bpm) than in the ST-negative group (+ 16 bpm). The initial increase in diastolic blood pressure (DBP) just after standing was significantly greater in the ST-positive group (+ 14 mmHg) than in the ST-negative group (+ 9 mmHg). Serum cortisol levels in the ST-positive patients aged over 20 years were higher and growth hormone levels in the patients under 20 years of age were lower than those in the ST-negative group. Autonomous nervous symptoms, transient DBP rise with increasing HR after standing, and endocrine dysfunctions are helpful for detecting OI related to long COVID.

Identifiants

pubmed: 39043760
doi: 10.1038/s41598-024-67815-y
pii: 10.1038/s41598-024-67815-y
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17025

Subventions

Organisme : Japan Agency for Medical Research and Development
ID : 22fk0108517h0001

Informations de copyright

© 2024. The Author(s).

Références

Nuzzo, J. B. & Gostin, L. O. The first 2 years of COVID-19: Lessons to improve preparedness for the next pandemic. JAMA 327, 217–218. https://doi.org/10.1001/jama.2021.24394 (2022).
doi: 10.1001/jama.2021.24394 pubmed: 34989763
Lippi, G., Sanchis-Gomar, F. & Henry, B. M. COVID-19 and its long-term sequelae: What do we know in 2023?. Pol. Arch. Intern. Med. https://doi.org/10.20452/pamw.16402 (2023).
doi: 10.20452/pamw.16402 pubmed: 37219465
Yang, J. et al. Definition and measurement of post-COVID-19 conditions in real-world practice: A global systematic literature review. BMJ Open 14, e077886. https://doi.org/10.1136/bmjopen-2023-077886 (2024).
doi: 10.1136/bmjopen-2023-077886 pubmed: 38233057 pmcid: 10806676
Shah, W., Hillman, T., Playford, E. D. & Hishmeh, L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ 372, n136. https://doi.org/10.1136/bmj.n136 (2021).
doi: 10.1136/bmj.n136 pubmed: 33483331
Otsuka, Y. et al. Clinical characteristics of Japanese patients who visited a COVID-19 aftercare clinic for post-acute sequelae of COVID-19/long COVID. Cureus 13, e18568. https://doi.org/10.7759/cureus.18568 (2021).
doi: 10.7759/cureus.18568 pubmed: 34760415 pmcid: 8571943
Tokumasu, K. et al. Clinical characteristics of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) diagnosed in patients with long COVID. Medicina (Kaunas) https://doi.org/10.3390/medicina58070850 (2022).
doi: 10.3390/medicina58070850 pubmed: 36295554
Yamamoto, Y. et al. Utility of serum ferritin for predicting myalgic encephalomyelitis/chronic fatigue syndrome in patients with long COVID. J. Clin. Med. https://doi.org/10.3390/jcm12144737 (2023).
doi: 10.3390/jcm12144737 pubmed: 38068484 pmcid: 10706870
Dani, M. et al. Autonomic dysfunction in ‘long COVID’: Rationale, physiology and management strategies. Clin. Med. (Lond.) 21, e63–e67. https://doi.org/10.7861/clinmed.2020-0896 (2021).
doi: 10.7861/clinmed.2020-0896 pubmed: 33243837
Tsuchida, T. et al. Treatment of long COVID complicated by postural orthostatic tachycardia syndrome—Case series research. J. Gen. Fam. Med. 25, 53–61. https://doi.org/10.1002/jgf2.670 (2024).
doi: 10.1002/jgf2.670 pubmed: 38240001
Hamrefors, V. et al. Syndromes of orthostatic intolerance and syncope in young adults. Open Heart 4, e000585. https://doi.org/10.1136/openhrt-2016-000585 (2017).
doi: 10.1136/openhrt-2016-000585 pubmed: 28674628 pmcid: 5471871
Ladlow, P. et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. Heart Rhythm 19, 613–620. https://doi.org/10.1016/j.hrthm.2021.12.005 (2022).
doi: 10.1016/j.hrthm.2021.12.005 pubmed: 34896622
Monaghan, A. et al. Orthostatic intolerance in adults reporting long COVID symptoms was not associated with postural orthostatic tachycardia syndrome. Front. Physiol. 13, 833650. https://doi.org/10.3389/fphys.2022.833650 (2022).
doi: 10.3389/fphys.2022.833650 pubmed: 35309052 pmcid: 8931464
Benarroch, E. E. Postural tachycardia syndrome: A heterogeneous and multifactorial disorder. Mayo Clin. Proc. 87, 1214–1225. https://doi.org/10.1016/j.mayocp.2012.08.013 (2012).
doi: 10.1016/j.mayocp.2012.08.013 pubmed: 23122672 pmcid: 3547546
Cabrera Martimbianco, A. L., Pacheco, R. L., Bagattini, A. M. & Riera, R. Frequency, signs and symptoms, and criteria adopted for long COVID-19: A systematic review. Int. J. Clin. Pract. 75, e14357. https://doi.org/10.1111/ijcp.14357 (2021).
doi: 10.1111/ijcp.14357 pubmed: 33977626
Raj, S. R. et al. Long-COVID postural tachycardia syndrome: An American Autonomic Society statement. Clin. Auton. Res. 31, 365–368. https://doi.org/10.1007/s10286-021-00798-2 (2021).
doi: 10.1007/s10286-021-00798-2 pubmed: 33740207 pmcid: 7976723
Khosravani, H. The dysfunction is in the details: Neurovascular changes in COVID-19. Can. J. Neurol. Sci. 48, 1–2. https://doi.org/10.1017/cjn.2020.150 (2021).
doi: 10.1017/cjn.2020.150 pubmed: 32665047
Sunada, N. et al. Hormonal trends in patients suffering from long COVID symptoms. Endocr. J. 69, 1173–1181. https://doi.org/10.1507/endocrj.EJ22-0093 (2022).
doi: 10.1507/endocrj.EJ22-0093 pubmed: 35491089
Yamamoto, Y. et al. Detection of male hypogonadism in patients with post COVID-19 condition. J. Clin. Med. https://doi.org/10.3390/jcm11071955 (2022).
doi: 10.3390/jcm11071955 pubmed: 36615100 pmcid: 9821428
Otsuka, Y. & Otsuka, F. Possibility of endocrine dysfunction in post coronavirus disease 2019 (COVID-19) condition. Endocr. J. 69, 1357. https://doi.org/10.1507/endocrj.EJ22-0459 (2022).
doi: 10.1507/endocrj.EJ22-0459 pubmed: 36216578
Klein, J. et al. Distinguishing features of long COVID identified through immune profiling. Nature 623, 139–148. https://doi.org/10.1038/s41586-023-06651-y (2023).
doi: 10.1038/s41586-023-06651-y pubmed: 37748514 pmcid: 10620090
Aizpurua-Perez, I., Arregi, A., Labaka, A., Martinez-Villar, A. & Perez-Tejada, J. Psychological resilience and cortisol levels in adults: A systematic review. Am. J. Hum. Biol. 35, e23954. https://doi.org/10.1002/ajhb.23954 (2023).
doi: 10.1002/ajhb.23954 pubmed: 37395446
Juruena, M. F., Bocharova, M., Agustini, B. & Young, A. H. Atypical depression and non-atypical depression: Is HPA axis function a biomarker? A systematic review. J. Affect. Disord. 233, 45–67. https://doi.org/10.1016/j.jad.2017.09.052 (2018).
doi: 10.1016/j.jad.2017.09.052 pubmed: 29150144
Miller, G. E., Chen, E. & Zhou, E. S. If it goes up, must it come down? Chronic stress and the hypothalamic–pituitary–adrenocortical axis in humans. Psychol. Bull. 133, 25–45. https://doi.org/10.1037/0033-2909.133.1.25 (2007).
doi: 10.1037/0033-2909.133.1.25 pubmed: 17201569
de Kloet, E. R. Glucocorticoid feedback paradox: A homage to Mary Dallman. Stress 26, 2247090. https://doi.org/10.1080/10253890.2023.2247090 (2023).
doi: 10.1080/10253890.2023.2247090 pubmed: 37589046
Agorastos, A. & Chrousos, G. P. The neuroendocrinology of stress: The stress-related continuum of chronic disease development. Mol. Psychiatry 27, 502–513. https://doi.org/10.1038/s41380-021-01224-9 (2022).
doi: 10.1038/s41380-021-01224-9 pubmed: 34290370
Sakurada, Y. et al. Trends in long COVID symptoms in Japanese teenage patients. Medicina (Kaunas) https://doi.org/10.3390/medicina59020261 (2023).
doi: 10.3390/medicina59020261 pubmed: 36837463
Johansson, M. et al. Circulating levels of growth hormone in postural orthostatic tachycardia syndrome. Sci. Rep. 11, 8575. https://doi.org/10.1038/s41598-021-87983-5 (2021).
doi: 10.1038/s41598-021-87983-5 pubmed: 33883597 pmcid: 8060383
Carfi, A., Bernabei, R., Landi, F., Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent symptoms in patients after acute COVID-19. JAMA 324, 603–605. https://doi.org/10.1001/jama.2020.12603 (2020).
doi: 10.1001/jama.2020.12603 pubmed: 32644129 pmcid: 7349096
Soriano, J. B. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22, e102–e107. https://doi.org/10.1016/S1473-3099(21)00703-9 (2022).
doi: 10.1016/S1473-3099(21)00703-9 pubmed: 34951953
in Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness The National Academies Collection: Reports funded by National Institutes of Health (2015).
Rowe, P. C. et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers–Danlos syndrome. J. Pediatr. 135, 494–499. https://doi.org/10.1016/s0022-3476(99)70173-3 (1999).
doi: 10.1016/s0022-3476(99)70173-3 pubmed: 10518084
Isojima, T. et al. Standardized centile curves and reference intervals of serum insulin-like growth factor-I (IGF-I) levels in a normal Japanese population using the LMS method. Endocr. J. 59, 771–780. https://doi.org/10.1507/endocrj.ej12-0110 (2012).
doi: 10.1507/endocrj.ej12-0110 pubmed: 22673406

Auteurs

Atsushi Kato (A)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Kazuki Tokumasu (K)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Koichiro Yamamoto (K)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Yuki Otsuka (Y)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Yasuhiro Nakano (Y)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Hiroyuki Honda (H)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Naruhiko Sunada (N)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Yasue Sakurada (Y)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Yui Matsuda (Y)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Toru Hasegawa (T)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Ryosuke Takase (R)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Keigo Ueda (K)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.

Fumio Otsuka (F)

Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan. fumiotsu@md.okayama-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH